真实世界英夫利西单抗药代动力学研究构建电子病历内嵌仪表板以指导儿童克罗恩病精准给药
多中心观察性研究纳入78例儿童克罗恩病患者,分析671个英夫利西单抗浓度,通过群体药代动力学建模发现血清白蛋白、抗英夫利西西单抗抗体、ESR和中性粒细胞CD64为药物清除生物标志物;诱导期最佳AUC目标为79,348 µg*h/mL,超过该目标者更易实现第52周无手术生化缓解(OR 4.3)。研究还将模型嵌入电子病历形成决策支持仪表板。
要点
- 诱导期英夫利西单抗AUC目标为79,348 µg*h/mL,与第14周生化缓解相关。
- 超过AUC目标者第52周无手术生化缓解率更高(OR 4.3)。
- 中性粒细胞CD64>6、ESR>30 mm/h、年龄<10岁、体重<30 kg预测亚治疗AUC。
核心结论
- 真实世界药代动力学模型可识别英夫利西单抗快速清除生物标志物并确定诱导期AUC目标。
- 基于模型引导的精准给药仪表板已嵌入电子病历,可在临床实时使用。
研究设计与样本
- 多中心观察性研究,纳入78例儿童克罗恩病患者,分析671个英夫利西单抗峰浓度和谷浓度。
- 使用药物耐受性检测法(Esoterix; LabCorp)测定浓度,采用非线性混合效应模型进行群体药代动力学建模。
主要发现
- 血清白蛋白、抗英夫利西单抗抗体、ESR和中性粒细胞CD64被识别为药物清除生物标志物。
- 第14周和第52周生化缓解者(粪钙卫蛋白<250 µg/g)在整个诱导期具有更高的英夫利西单抗暴露(AUC)。
关键数值与推荐
- 生化缓解定义为粪钙卫蛋白<250 µg/g。
临床怎么用
- 可利用基线中性粒细胞CD64、ESR、年龄和体重识别亚治疗暴露高风险患儿。
- 诱导期可参考AUC目标79,348 µg*h/mL进行模型引导的精准给药。
- 电子病历内嵌仪表板可实时辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Standard-of-care infliximab dosing regimens were developed prior to the routine use of therapeutic drug monitoring and identification of target concentrations. Not surprisingly, subtherapeutic infliximab concentrations in pediatric Crohn's disease (CD) are common. The primary aim was to conduct a real-world pharmacokinetic (PK) evaluation to discover blood biomarkers of rapid clearance, identify exposure targets, and a secondary aim to translate PK modeling to the clinic. In a multicenter observational study, 671 peak and trough infliximab concentrations from 78 patients with CD were analyzed with a drug-tolerant assay (Esoterix; LabCorp, Calabasas, CA). Individual area under the curve (AUC) estimates were generated as a measure of drug exposure over time. Population PK modeling (nonlinear mixed-effect modeling) identified serum albumin, antibody to infliximab, erythrocyte sedimentation rate (ESR), and neutrophil CD64 as biomarkers for drug clearance. Week 14 and week 52 biochemical remitters (fecal calprotectin < 250 µg/g) had higher infliximab exposure (AUC) throughout induction. The optimal infliximab AUC target during induction for week 14 biochemical remission was 79,348 µg*h/mL (area under the receiver operating characteristic curve (AUROC) 0.77, [0.63-0.90], 85.7% sensitive, and 64.3% specific) with those exceeding the AUC target more likely to achieve a surgery-free week 52 biochemical remission (OR 4.3, [1.2-14.6]). Pretreatment predictors for subtherapeutic week 14 AUC included neutrophil CD64 > 6 (OR 4.5, [1.4-17.8]), ESR > 30 mm/h (OR 3.8, [1.4-11]), age < 10 years old (OR 4.2, [1.2-20]), and weight < 30 kg (OR 6.6, [2.1-25]). We created a decision-support PK dashboard with an iterative process and embedded the modeling program within the electronic health record. Model-informed precision dosing guided by real-world PKs is now available at the bedside in real-time.
引用
- Xiong Y, Mizuno T, Colman R, et al. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clin Pharmacol Ther. 2021. PMID: 33354765. doi:10.1002/cpt.2148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。